Cynata Therapeutics’ clinical trial gains momentum

Company News

by Jessica Amir

Cynata Therapeutics (ASX:CYP) has announced it commenced patient dosing in the first ever clinical trial of stem cell therapy for graft-versus host disease therapy.

The Australian stem cell and regenerative medicine company says the trial is a major achievement in the evolution of the company.

The company's Phase 1 trial of CYP-001 is also being recruited at six centres in the UK and Australia.

At the same time, Cynata Therapeutics also announced it secured over $60 million through a FUJIFILM partnership and a license option for CYP-001 in graft-versus host disease (GvHD)

Shares in Cynata Therapeutics (ASX:CYP) are trading 3.1 per cent higher to $0.66.
 

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.